Novo Nordisk stock news
On July 31, 2026, a federal judge in New Jersey ruled that a class--action lawsuit against Novo Nordisk (NVO) can proceed. The litigation alleges that the company and its executives misled investors regarding the clinical trial prospects of the weight--loss drug CagriSema, which led to a 20% stock price decline in 2024. The ruling allows the case to enter the discovery phase, potentially exposing the company to legal liabilities and impacting investor sentiment ahead of its Q2 earnings release.